Medication updates for new anticoagulants

XMLWordPrintable

    • Type: Terminology
    • Resolution: Fixed
    • Priority: Minor
    • Component/s: ValueSet
    • None
    • Hide
      Changes were made during the April 1 2013 annual update to address these issues. From the April 1 Release Notes:

      For measure NQF 0436/CMS 71 Stroke-3 Ischemic stroke
      • Updated the “Anticoagulant Therapy RxNorm Value Set (2.16.840.1.113883.3.117.1.7.1.200)". Medications that are in the Oral Factor Xa Inhibitor Value Set are added into the Anticoagulant Therapy RxNorm Value Set. Some of the RxNorm codes are remapped, inactive RxNorm codes are removed.

      For measure NQF 0435/CMS 104 Stroke-2 and NQF 0438/CMS 72 Stroke-5:
      • Updated the "Antithrombotic Therapy RxNorm Value Set (2.16.840.1.113883.3.117.1.7.1.201)". Some of the RxNorm codes are remapped. Inactive RxNorm codes are removed.

      (Note: While the release notes didn't specifically mention the inclusion of Rivaroxaban and Apixaban, they are included in the updated value set)

      Revised specifications for the eMeasures are available on CMS' website.
      Show
      Changes were made during the April 1 2013 annual update to address these issues. From the April 1 Release Notes: For measure NQF 0436/CMS 71 Stroke-3 Ischemic stroke • Updated the “Anticoagulant Therapy RxNorm Value Set (2.16.840.1.113883.3.117.1.7.1.200)". Medications that are in the Oral Factor Xa Inhibitor Value Set are added into the Anticoagulant Therapy RxNorm Value Set. Some of the RxNorm codes are remapped, inactive RxNorm codes are removed. For measure NQF 0435/CMS 104 Stroke-2 and NQF 0438/CMS 72 Stroke-5: • Updated the "Antithrombotic Therapy RxNorm Value Set (2.16.840.1.113883.3.117.1.7.1.201)". Some of the RxNorm codes are remapped. Inactive RxNorm codes are removed. (Note: While the release notes didn't specifically mention the inclusion of Rivaroxaban and Apixaban, they are included in the updated value set) Revised specifications for the eMeasures are available on CMS' website.

      As of January 1, 2013, the parallel Stoke Core Measures (STK -2, 3 & 5) have included the following, as acceptable medications within the therapy lists.

      Xarelto/Rivaroxaban
      Eliquis/Apixaban

      1.)Will these medications be added in the April 1, 2013 update?

            Assignee:
            Abt Associate (Inactive)
            Reporter:
            Kimberly M. Bodine (Inactive)
            Votes:
            0 Vote for this issue
            Watchers:
            4 Start watching this issue

              Created:
              Updated:
              Resolved: